[{"id":"a6d2ab39-a519-4fdb-aca6-2f51916bba32","acronym":"","url":"https://clinicaltrials.gov/study/NCT01468532","created_at":"2021-01-18T06:06:48.742Z","updated_at":"2024-07-02T16:36:32.814Z","phase":"Phase 1/2","brief_title":"Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT01468532","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" IGF1 • CHGA","pipe":"","alterations":" ","tags":["IGF1 • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • Signifor (pasireotide) • Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 07/20/2017","primary_completion_date":" 07/20/2017","study_txt":" Completion: 07/20/2017","study_completion_date":" 07/20/2017","last_update_posted":"2021-03-25"},{"id":"3bea20a1-a979-4959-b4e2-6a88db539ae8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00446082","created_at":"2021-01-18T01:34:38.995Z","updated_at":"2024-07-02T16:36:37.050Z","phase":"Phase 1","brief_title":"Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease","source_id_and_acronym":"NCT00446082","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1 • CHGA","pipe":" | ","alterations":" IGF1 elevation","tags":["IGF1 • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGF1 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2020-12-21"},{"id":"95042f6a-45be-4701-aa7b-d23a629aa6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01652547","created_at":"2021-01-18T07:07:16.540Z","updated_at":"2024-07-02T16:36:37.035Z","phase":"Phase 1","brief_title":"A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma","source_id_and_acronym":"NCT01652547","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CCND1 • S100B","pipe":"","alterations":" ","tags":["CCND1 • S100B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-21"},{"id":"eb761fb6-c868-447b-b376-77638b3bacc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01646684","created_at":"2021-01-18T07:05:32.698Z","updated_at":"2024-07-02T16:36:37.058Z","phase":"Phase 1","brief_title":"Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT01646684","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/08/2013","start_date":" 03/08/2013","primary_txt":" Primary completion: 11/13/2018","primary_completion_date":" 11/13/2018","study_txt":" Completion: 11/13/2018","study_completion_date":" 11/13/2018","last_update_posted":"2020-12-21"},{"id":"ce540c17-ccf2-4643-bcd9-84218b6de1fa","acronym":"Passion I","url":"https://clinicaltrials.gov/study/NCT01283542","created_at":"2021-02-09T07:54:16.394Z","updated_at":"2024-07-02T16:37:00.170Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.","source_id_and_acronym":"NCT01283542 - Passion I","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/26/2012","start_date":" 11/26/2012","primary_txt":" Primary completion: 09/12/2017","primary_completion_date":" 09/12/2017","study_txt":" Completion: 09/12/2017","study_completion_date":" 09/12/2017","last_update_posted":"2019-04-26"},{"id":"97cb39b3-aeeb-4a62-883e-9aa3b0114e3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00859040","created_at":"2021-02-02T07:52:11.180Z","updated_at":"2025-02-25T15:49:58.207Z","phase":"Phase 2","brief_title":"Monthly SOM230C for Recurrent or Progressive Meningioma","source_id_and_acronym":"NCT00859040","lead_sponsor":"Patrick Y. Wen, MD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-10-27"},{"id":"5d25f25f-7d0f-47fd-9b98-bf12e6b4ccfe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639352","created_at":"2021-01-18T07:02:59.200Z","updated_at":"2024-07-02T16:37:20.000Z","phase":"Phase 2","brief_title":"Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT01639352","lead_sponsor":"Lynn Feun","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2017-07-12"},{"id":"f53822ca-4ff9-4c2d-91b3-a76d67c3552d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01488487","created_at":"2021-01-18T06:13:26.936Z","updated_at":"2025-02-25T15:52:23.706Z","phase":"Phase 2","brief_title":"Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma","source_id_and_acronym":"NCT01488487","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2016-04-07"}]